ANRO

At a glance

Alto Neuroscience, Inc. (ANRO) is listed on NYSE and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Mountain View, United States and has 68 employees. The company is worth $860.97M. The share price is 41.5% below its 52-week high of $37.48. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $14.73M. In that quarter, 2 of them reduced the position. Over the last 30 days, company insiders sold $3.57M of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$860.97M

P/E

—

Forward P/E

—

P/B

3.5x

Dividend yield

0.00%

Payout

—

EPS

-$2.31

ROE

-49.17%

Profit margin

0.00%

Revenue growth

—

Beta

1.34

52-week high

$37.48

52-week low

$6.72

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• IE
  Israel Englander− Reduced

  Millennium Management · Q2 2026
  $14.73M

  558.32K shares · 0.0% of portfolio
• SC
  Steve CohenHeld

  Point72 Asset Management · Q2 2026
  $13.27M

  502.95K shares · 0.0% of portfolio
• TS
  Two Sigma− Reduced

  Two Sigma Investments · Q2 2026
  $3.89M

  147.3K shares · 0.0% of portfolio

Indicators, year by year

The last 2 closed years, each at that year’s closing price and reported numbers.

Median of the years shown; P/E years above 200x are left out.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company